Literature DB >> 11598400

TINU syndrome associated with reduced complement levels.

P A Conz1, M Milan, L Bragantini, G La Greca, P A Bevilacqua.   

Abstract

The TINU syndrome (tubulointerstitial nephritis and uveitis) was first described by Dobrin et al. in 1975. Since then, more than 50 cases have been documented each with diverse immunopathogenetic and genetic characteristics. The aim of this report is to describe a case of TINU associated with reduced complement levels. We profile a 48-year-old white female with persistently reduced C4 complement levels during the acute phase of the pathology and with an unaltered immunologic profile. Renal biopsy evidenced a significant lymphocytic interstitial infiltration. Immunohistochemical studies of the interstitium infiltrates was positive for the presence of the T (CD3) markers (CD4 > CD8). Steroid therapy yielded a complete regression of the symptomatology with normalization of the complement levels. We suggest that it is possible to hypothesize that the various immunologic alterations associated with TINU, including the transient reduction complement levels, may be secondary to multiple inflammatory mechanisms which express themselves throughout the pathology. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598400     DOI: 10.1159/000046096

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Tubulointerstitial nephritis and uveitis syndrome associated with hyperthyroidism.

Authors:  Itaru Ebihara; Kouichi Hirayama; Joichi Usui; Masanori Seki; Fujiko Higuchi; Takaaki Oteki; Masaki Kobayashi; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

2.  A Rare Case of Tubulointerstitial Nephritis and Uveitis Syndrome Treated with a Multi-Specialty Approach.

Authors:  Boonkit Purt; Siri Hiremath; Sarah Smith; Sergul Erzurum; Erdal Sarac
Journal:  Am J Case Rep       Date:  2016-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.